Search our Database of Scientific Publications and Authors

I’m looking for a

    710 results match your criteria Pruritus and Systemic Disease

    1 OF 15

    Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
    J Eur Acad Dermatol Venereol 2018 May;32(5):657-682
    Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.
    This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Read More

    Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
    J Dermatol 2018 Apr 17. Epub 2018 Apr 17.
    Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.
    The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE-052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients. In the QBX1-1 study, the cutaneous safety of JTE-052 ointment by a patch test and a photo patch test was assessed in an intra-individual comparative study using placebo ointment, white petrolatum and non-application as comparators. Read More

    Lymphocytic Mural Folliculitis Resembling Epitheliotropic Lymphoma in Tigers ( Panthera tigris).
    Vet Pathol 2018 Jan 1:300985818766213. Epub 2018 Jan 1.
    2 Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA.
    A striking form of lymphocytic mural folliculitis is described in 6 tigers ( Panthera tigris). Clinically, all tigers exhibited regionally extensive chronic, variably waxing and waning alopecia with minimal scaling and crusting most pronounced over the head, neck, and shoulders. More severely affected tigers exhibited marked hyperpigmentation and lichenification. Read More

    The Major Orphan Forms of Ichthyosis are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc22 Polarization in Blood.
    J Invest Dermatol 2018 Apr 13. Epub 2018 Apr 13.
    The ichthyoses are rare skin disorders with immune and barrier aberrations. Identifying blood phenotypes may advance targeted-therapeutics.We aimed to compare frequencies of skin homing/CLA vs. Read More

    Colchicine may be of therapeutic benefit in prurigo pigmentosa.
    Pediatr Dermatol 2018 Apr 11. Epub 2018 Apr 11.
    Department of Dermatology, İzmir Katip Çelebi University, İzmir, Turkey.
    Prurigo pigmentosa (PP) is a rare inflammatory skin disease. Neutrophil-mediated inflammation is considered to be responsible for the etiopathogenesis of PP. We consider that colchicine may be an effective agent in the treatment of PP since it exerts an antiinflammatory effect by inhibiting neutrophil chemotaxis. Read More

    [Chronic prurigo].
    Hautarzt 2018 Apr;69(4):321-330
    Kompetenzzentrum Chronischer Pruritus (KCP), Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland.
    Chronic prurigo is a disease characterized by the presence of chronic pruritus and singular or multiple usually hyperkeratotic symmetrically distributed itchy papules, nodules, and/or plaques. This condition is difficult to treat and leads to a substantial impairment of the quality of life. It may originate from dermatological, systemic, neurological, psychiatric/psychosomatic, multifactorial or unknown conditions causing itch, which lead to prolonged scratching behavior and sensitization mechanisms and ultimately to the development of pruriginous lesions. Read More

    Causes, pathophysiology, and treatment of pruritus in the mature patient.
    Clin Dermatol 2018 Mar - Apr;36(2):140-151. Epub 2017 Oct 17.
    Department of Dermatology & Miami Itch Center at the University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA. Electronic address:
    Chronic itch is a common and debilitating health condition in the elderly. There are several common causes of itch in the mature population, such as skin xerosis, immunosenescence, and neuropathic changes. In addition, skin diseases, such as seborrheic dermatitis and stasis dermatitis, systemic conditions (end-stage renal disease and diabetes), or psychogenic derailments, such as depression, anxiety, and dementia, can all serve as triggers of pruritus. Read More

    Itch in dermatomyositis: the role of increased skin interleukin-31.
    Br J Dermatol 2018 Mar 1. Epub 2018 Mar 1.
    Corporal Michael J. Crescenz VAMC, Philadelphia, PA.
    Background: Interleukin-31 (IL-31) is implicated in pruritus associated with pruritic skin diseases like atopic dermatitis. Although pruritus is a prominent feature in dermatomyositis (DM), few studies have evaluated the pathogenesis of DM-associated itch.

    Objectives: Our goals were to establish the prevalence of itch in DM, and to investigate the role of IL-31 in DM-related itch. Read More

    [New aspects in systemic treatment of atopic dermatitis].
    Hautarzt 2018 Mar;69(3):217-224
    Abteilung für Immundermatologie und experimentelle Allergologie, Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
    In severe cases of atopic dermatitis (AD) systemic treatment is indicated. So far, cyclosporine and systemic glucocorticosteroids represented the only systemic treatment options approved for the indications of AD in Germany; however, from clinical practice there is increasing evidence for beneficial therapeutic effects in AD by other immunosuppressive or immunomodulatory substances, such as mycophenolate, methotrexate, alitretinoin and ustekinumab. Beyond this, ongoing research activities focus on a better understanding of genetic and immunological aspects of this chronic inflammatory skin disease. Read More

    Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.
    Am J Clin Oncol 2018 Feb 21. Epub 2018 Feb 21.
    Seoul National University Hospital, Seoul, Republic of Korea.
    Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored.

    Materials And Methods: A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806). Read More

    Vitamin D shows in vivo efficacy in a placebo-controlled, double-blinded, randomised clinical trial on canine atopic dermatitis.
    Vet Rec 2018 Apr 1;182(14):406. Epub 2018 Feb 1.
    Clinic of Small Animal Medicine, Ludwig Maximilian University, Munich, Germany.
    Atopic dermatitis (AD) in dogs is among the most common skin diseases in small animal practice. It is an inflammatory disease based on a genetic predisposition to develop hypersensitivity against environmental and food allergens and typical clinical signs up exposure. Treatment sometimes can be difficult and associated with adverse effects. Read More

    Epigallocatechin-3-gallate attenuates acute and chronic psoriatic itch in mice: Involvement of antioxidant, anti-inflammatory effects and suppression of ERK and Akt signaling pathways.
    Biochem Biophys Res Commun 2018 02 1;496(4):1062-1068. Epub 2018 Feb 1.
    Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Department of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, 215123, China. Electronic address:
    Chronic itch is a distressing symptom of many skin diseases and negatively impacts quality of life. However, there is no medication for most forms of chronic itch, although antihistamines are often used for anti-itch treatment. Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol, exhibits anti-oxidative and anti-inflammatory properties. Read More

    Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    Lancet Oncol 2018 Mar 19;19(3):416-426. Epub 2018 Jan 19.
    National Cancer Institute, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
    Background: Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. Read More

    Lichen planus pemphigoides treated with ustekinumab.
    Cutis 2017 Dec;100(6):415-418
    Advanced Desert Dermatology/Midwestern University, Glendale, Arizona, USA.
    A 71-year-old woman presented with pink to violaceous, flat-topped, polygonal papules on the volar wrists, extensor elbows, and bilateral lower legs of 3 years' duration. She also had erythematous, violaceous, infiltrated plaques with microvesiculation on the bilateral thighs of several months' duration. She reported pruritus, burning, and discomfort. Read More

    Fixed Drug Eruption to Supplement Containing Ginkgo Biloba and Vinpocetine: A Case Report and Review of Related Cutaneous Side Effects.
    J Clin Aesthet Dermatol 2017 Oct 1;10(10):44-47. Epub 2017 Oct 1.
    Dr. Cohen is from the Department of Dermatology at the University of California San Diego, La Jolla, California.
    Fixed drug eruption is a cutaneous reaction to a systemic agent that typically presents as an annular or oval erythematous patch or blister and subsequently resolves with postinflammatory hyperpigmentation at the site. leaf extract and vinpocetine are nutritional supplements used to enhance memory in patients with dementia and age-related memory impairment conditions such as Alzheimer's disease. To describe a fixed drug eruption in a man who repeatedly developed pruritus and macular erythema on his distal penile shaft after ingesting a natural product containing and vinpocetine. Read More

    [Lichen ruber planus : Better understanding, better treatment!]
    Hautarzt 2018 Feb;69(2):100-108
    Klinik für Dermatologie, Venerologie und Allergologie, Campus Homburg, Gebäude 6.7, Universität des Saarlandes, Homburg, Deutschland.
    Lichen ruber, also called lichen ruber planus or lichen planus (LP), is a noncontagious inflammatory skin disease. LP is the main representative and namesake of the group of lichenoid diseases, which are characterized by small papules often accompanied by severe itching. With 65% of cases, LP is primarily a disease of the mucous membranes. Read More

    Phosphodiesterase 4 inhibitors.
    J Am Acad Dermatol 2018 Mar 15;78(3S1):S43-S52. Epub 2017 Dec 15.
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address:
    Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited their use. More targeted options with fewer systemic and cutaneous side effects are needed for treating AD. Read More

    Emerging Treatment Options in Atopic Dermatitis: Topical Therapies.
    Dermatology 2017 8;233(5):333-343. Epub 2017 Dec 8.
    Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark.
    Atopic dermatitis is a chronic inflammatory skin disorder affecting children and adults, with the majority presenting mild to moderate disease severity. The use of topical corticosteroids (TCSs) in combination with emollients has been the mainstay for treating mild to moderate atopic dermatitis since the 1950s, and as a supplement to systemic treatment in severe disease. However, while very effective, TCSs are often accompanied by poor adherence due to corticophobia (fear of using corticosteroids in patients or doctors), unwanted side effects, and in some cases insufficient clinical response. Read More

    Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Br J Dermatol 2018 Mar 3;178(3):659-662. Epub 2017 Dec 3.
    Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
    Aim: To assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, for the treatment of mild or moderate atopic dermatitis (AD) in two phase III studies (AD-301 and AD-302).

    Design And Setting: Two identically designed multicentre, double-blind randomized controlled trials were conducted in the U.S. Read More

    Systemic granulomatous disease in dairy cattle during a dicyandiamide feeding trial.
    N Z Vet J 2018 Mar 20;66(2):108-113. Epub 2017 Dec 20.
    c Institute of Veterinary, Animal and Biomedical Sciences , Massey University , Private Bag 11-222, Palmerston North , 4442 , New Zealand.
    Case History: Mature, in-calf, non-lactating, Friesian or Friesian-cross cows were fed dicyandiamide (DCD) at daily doses of 0.15 g/kg (Group 1; n=31), 0.45 g/kg (Group 2; n=21) and 0. Read More

    Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    Br J Dermatol 2017 Nov 28. Epub 2017 Nov 28.
    Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.
    Background: Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U. Read More

    The triad of pruritus, xanthomas, and cholestasis: Two cases and a brief review of the literature.
    Pediatr Dermatol 2017 Nov;34(6):e305-e308
    University of Mississippi Medical Center, Jackson, MS, USA.
    When encountered in children, xanthomas are most commonly associated with a group of disorders known as familial hyperlipidemias. Aside from cosmetic concerns, these xanthomas are typically asymptomatic, but when generalized pruritus is a prominent associated symptom, clinicians should consider a different set of diagnoses that includes cholestasis of the liver. In this article we present two illustrative cases of children with cholestatic disease, pruritus, and xanthomas and discuss other disorders that may include this triad. Read More

    MrgprA3 shows sensitization to chloroquine in an acetone-ether-water mice model.
    Neuroreport 2017 Dec;28(17):1127-1133
    aDepartment of Physiology, School of Medicine and Life Sciences bKey Laboratory of Prevention and Treatment of Chinese Medicine in Neurological Disease, Nanjing University of Chinese Medicine cDepartment of Biochemistry, College of Life Sciences, Nanjing Normal University, Nanjing dDepartment of Physiology, College of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, China.
    Chronic itch, a distressing symptom of many cutaneous and systemic diseases, significantly impairs quality of life. However, its underlying molecular mechanism is still unclear. Mas-related G protein-coupled receptor A3 (MrgprA3) is considered an itch-specific receptor. Read More

    Atopic Dermatitis: Managing the Itch.
    Adv Exp Med Biol 2017 ;1027:161-177
    Department of Dermatology, George Washington University, Washington, DC, USA.
    Atopic dermatitis has a substantial impact on sleep, appearance, psychological well-being, and other qualities of life. The visual appearance of lichenification, cheilitis, hyperpigmentation, ichthyosis, and erythema can be socially stigmatizing, and treatment of these symptoms is challenging. In managing pruritus in patients, practitioners should assess and document pruritus through questionnaires at each routine visit. Read More

    Aprepitant for the Treatment of Chronic Refractory Pruritus.
    Biomed Res Int 2017 19;2017:4790810. Epub 2017 Sep 19.
    Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Read More

    Use of oral antidepressants in patients with chronic pruritus: A systematic review.
    J Am Acad Dermatol 2017 Dec 21;77(6):1068-1073.e7. Epub 2017 Oct 21.
    Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
    Background: Chronic pruritus is a common skin symptom with marked impact on quality of life. Adequate treatment can be challenging for clinicians, demanding the exploration of new treatment options such as oral antidepressants.

    Objective: To evaluate the use of oral antidepressants in chronic pruritus by a systematic overview of the available relevant literature. Read More

    The relationship between pruritus and clinical variables in patients with psoriasis.
    An Bras Dermatol 2017 Jul-Aug;92(4):470-473
    Department of Biostatistics, Medical Faculty, Bezmialem Vakif University - Istanbul, Turquia.
    Background:: Pruritus is the most commonly occurring subjective symptom of dermatological disease. Published data on both prevalence and intensity of pruritus in psoriasis is limited.

    Objective:: In this study we aimed to investigate the prevalence of pruritus and its relation with psoriasis area severity index, body mass index and presence of systemic disease in patients with psoriasis. Read More

    Therapeutic pipeline for atopic dermatitis: End of the drought?
    J Allergy Clin Immunol 2017 Sep;140(3):633-643
    Department of Dermatology and Allergy, University of Bonn, and the Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
    Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation. Most agents are in phase 2 clinical trials. Read More

    Skin as a marker of general feline health: Cutaneous manifestations of systemic disease.
    J Feline Med Surg 2017 Sep;19(9):948-960
    Small Animal Specialist Hospital, Sydney, NSW, Australia, and Associate Lecturer, University of Sydney, NSW, Australia.
    Practical relevance: Although most skin lesions occur due to diseases primarily affecting the skin, some reflect important systemic diseases. Such lesions may relate directly to the systemic disease, or may occur due to secondary skin diseases that develop because of immunosuppression. Early recognition of skin changes as a marker of systemic disease will maximise patient outcomes. Read More

    Therapeutic comparison between treatments for Vulvar Lichen Sclerosus: study protocol of a randomized prospective and controlled trial.
    BMC Womens Health 2017 Aug 10;17(1):61. Epub 2017 Aug 10.
    Postgraduate Program in Biophotonics Applied to Health Sciences, Nove de Julho University/UNINOVE, 249 Vergueiro Street, Liberdade, São Paulo, SP, 01504-001, Brazil.
    Background: Vulvar lichen sclerosus (VLS) is a lymphocyte-mediated disease of unknown etiology that can cause intense itching as well stenosis, hindering the evacuation and urination. It can also limit the sex life due to severe local pruritus, pain and dyspareunia (pain during sexual intercourse). The standard treatment for this disease is the use of topical corticosteroids to reduce the clinical symptoms and to try to increase disease-free intervals. Read More

    Mastocytosis: from a Molecular Point of View.
    Clin Rev Allergy Immunol 2017 Jul 19. Epub 2017 Jul 19.
    Floridsdorf Allergy Center (FAZ), Vienna, Austria.
    Mast cells (MCs) are physiologically activated by binding of stem cell factor (SCF) to the extracellular domains of the Kit receptor. This binding increases the proliferation and prolongs the survival of normal mature MCs, as well as intensifies the release of mediators. In mastocytosis, somatic mutations of the coding Kit gene cause autocrine dysregulation and lead to constitutive KIT activation even in the absence of its ligand SCF. Read More

    Treatment of Uremic Pruritus: A Systematic Review.
    Am J Kidney Dis 2017 Nov 15;70(5):638-655. Epub 2017 Jul 15.
    Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Section of Nephrology, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Chronic Disease Innovation Centre, Seven Oaks Hospital, Winnipeg, Manitoba, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address:
    Background: Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined.

    Study Design: Systematic review. Read More

    Possible role of Helicobacter pylori in diseases of dermatological interest.
    J Biol Regul Homeost Agents 2017 APR-JUN;31(2 Suppl. 2):57-77
    Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
    Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. Read More

    Blood lead level is a positive predictor of uremic pruritus in patients undergoing hemodialysis.
    Ther Clin Risk Manag 2017 12;13:717-723. Epub 2017 Jun 12.
    Department of Nephrology and Division of Clinical Toxicology, Chang Gung Memorial Hospital, Linkou Medical Center.
    Although uremic pruritus (UP) is a common and annoying symptom for end-stage renal disease patients on hemodialysis (HD) and peritoneal dialysis, its pathogenesis is poorly understood. However, systemic inflammation is one of the possible pathogenesis of UP, and blood lead level (BLL) has been noted to be associated with inflammation and nutritional status in long-term HD patients. There might be an interaction or association, therefore, between BLL and UP through systemic inflammation. Read More

    Management of poorly controlled indolent systemic mastocytosis using narrowband UVB phototherapy.
    Cutis 2017 May;99(5):E30-E33
    Georgetown University Hospital/Washington Hospital Center, Washington, DC, USA.
    The mastocytoses comprise a group of proliferative stem cell disorders defined by the abnormal accumulation of mast cells (MCs) in the skin or other body tissues including the bone marrow, gastrointestinal tract, and liver. Systemic mastocytosis is defined by the presence of one major and one minor criterion or 3 minor criteria delineated by the World Health Organization (WHO). We present the case of a 57-year-old woman with a 10-year history of red-brown pruritic maculopapular lesions on the upper and lower extremities and trunk who was originally diagnosed with cutaneous mastocytosis. Read More

    Porokeratosis ptychotropica responding to photodynamic therapy: An alternative treatment for a refractory disease.
    Photodermatol Photoimmunol Photomed 2017 Sep 20;33(5):271-274. Epub 2017 Jun 20.
    Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
    Background: Porokeratosis ptychotropica (PP) is a rare variant of porokeratosis with a special predisposition to affect body folds, particularly the intergluteal cleft. This disease is resistant to most topical and systemic treatments, as shown in the review of the literature we provide here. Itching and discomfort are often a difficult problem to solve. Read More

    Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
    Dermatol Online J 2017 May 15;23(5). Epub 2017 May 15.
    University of Vermont College of Medicine, Burlington, Vermont.
    Atopic dermatitis (AD) is a common inflammatory dermatosis characterized by pruritus, erythema, induration, and lichenification. Current treatment options for generalized atopic dermatitis are limited and have potentially serious adverse effects, especially in patients with severe, chronic AD who frequently require systemic anti-inflammatory agents. Apremilast, an oral phosphodiesterase-4 inhibitor, was FDA approved in September 2014 for the treatment of moderate-to-severe plaque psoriasis. Read More

    Dermatological diseases in palliative care patients: a prospective study of 271 patients.
    J Dtsch Dermatol Ges 2017 Jun 17;15(6):621-627. Epub 2017 May 17.
    Gerontology Institute "13 November", Skopje, Republic of Macedonia.
    Background: Numerous risk factors place palliative care patients at an increased risk of skin infections, dermatitis, and pressure sores. Furthermore, worsening of chronic skin disorders can be expected, as well as the development of treatment-induced and malignancy-related dermatoses. The objective of the present study was to investigate the prevalence and treatment of dermatological conditions in patients receiving hospital-based palliative care. Read More

    The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Vet Dermatol 2017 Oct 17;28(5):485-e113. Epub 2017 May 17.
    Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 311 Diagnostic Medical Center, 300 West Drake, Fort Collins, CO, 80524, USA.
    Background: Oclacitinib is a selective Janus kinase inhibitor for the treatment of canine allergic pruritus and atopic dermatitis in dogs. Glucocorticoids and ciclosporin increase urinary tract infection (UTI) frequency in dogs with inflammatory skin disease.

    Objective: Prospective study to evaluate the frequency of UTI and subclinical bacteriuria in dogs with allergic dermatitis receiving oclacitinib. Read More

    Chronic Pruritus: Current and Emerging Treatment Options.
    Drugs 2017 Jun;77(9):999-1007
    Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Von-Esmarch-Str. 58, Münster, 48149, Germany.
    Chronic pruritus remains a central societal issue because of its high occurrence and the substantial decrease in quality of life it may cause to affected individuals. Not only dermatological conditions, but also systemic, neurological, or psychiatric diseases may lead to chronic pruritus. Additionally, various underlying conditions may coexist or the cause may be unknown. Read More

    An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease.
    Arch Dermatol Res 2017 Aug 21;309(6):443-452. Epub 2017 Apr 21.
    Department of Dermatology, University of Naples Federico II, Naples, Italy.
    Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease which predominantly affects children. However, AD may persist until adulthood (persistent AD), or directly start in adults (adult-onset AD). AD often shows a non-flexural rash distribution, and atypical morphologic variants in adults and specific diagnostic criteria are lacking. Read More

    Long-term anti-itch effect of botulinum neurotoxin A is associated with downregulation of TRPV1 and TRPA1 in the dorsal root ganglia in mice.
    Neuroreport 2017 Jun;28(9):518-526
    aDepartment of Neurology, the Second Affiliated Hospital of Soochow University bInstitute of Neuroscience cJiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Department of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou dSuqian First Hospital, Suqian, China.
    Itch is a common symptom in patients with skin and systemic diseases, but the effective treatment is limited. Here, we evaluated the anti-itch effects of the botulinum toxin type A (BoNT/A) using acute and chronic dry skin itch mouse models, which were induced by compound 48/80, chloroquine, and a mixture of acetone-diethylether-water treatment, respectively. Pretreatment of intradermal BoNT/A exerted long-term inhibitory effects on compound 48/80-induced and chloroquine-induced acute itch on days 1, 3, 7, and 14, but not on day 21, in mice. Read More

    [Pruritus of the scalp : Simply pulling out your hair?]
    Hautarzt 2017 Jun;68(6):449-456
    Abteilung Klinische Sozialmedizin, Schwerpunkt: Berufs- und Umweltdermatologie, Universitätsklinikum, Ruprecht-Karls-Universität Heidelberg, Voßstr. 2, 69115, Heidelberg, Deutschland.
    Scalp pruritus is a frequent symptom and can be caused by dermatologic diseases, contact allergies, neurologic, psychiatric/somatoform and systemic diseases. In daily clinical practice scalp pruritus is a diagnostic and therapeutic challenge, especially if no detectable lesions are present. A detailed patient history and the inspection of scalp and the skin of the whole body are essential for diagnosis. Read More

    Association of Dermatoses with Duration and Quantum of Alcohol Intake: A Comparative Cross-sectional Study.
    Indian J Dermatol 2017 Mar-Apr;62(2):184-190
    Department of Dermatology, Dr. D.Y. Patil Medical College and Hospital, Pune, Maharashtra, India.
    Background: Chronic alcohol intake impacts skin directly, through organ dysfunction or by modifying preexisting dermatoses. However, dermatoses afflicting chronic alcoholics figure in a few studies only.

    Aim: This study aims to correlate the spectrum of dermatoses in chronic alcoholics with the quantum/duration of alcohol intake and raised liver transaminases. Read More

    The efficacy and safety of intravenous lidocaine for analgesia in the older adult: a literature review.
    Br J Pain 2017 Feb 24;11(1):23-31. Epub 2016 Oct 24.
    North Devon District Hospital, Barnstaple, UK.
    Opioids remain the mainstay of analgesia for the treatment of moderate to severe acute pain. Even in the young, the use of opioids can be associated with an increased incidence of post-operative complications such as respiratory depression, vomiting, pruritus, excessive sedation, slowing of gastrointestinal function, and urinary retention. The need to manage acute pain in the older patient is becoming more common as the population ages, and increasingly older patients are undergoing more major surgery. Read More

    [Pathophysiology of atopic blepharokeratoconjunctivitis].
    Ophthalmologe 2017 Jun;114(6):504-513
    Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland.
    Atopic dermatitis (AD) is a systemic inflammatory disease, which is characterized by pronounced eczema and pruritus. In addition to the involvement of the entire integument, the periocular lid skin and the surface of the eye are frequently involved. Ocular involvement may occur solely without dermatitis of facial or body skin. Read More

    Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.
    Postgrad Med 2017 Aug 27;129(6):581-589. Epub 2017 Mar 27.
    e Merck & Co., Inc. , Kenilworth , NJ , USA.
    Allergic rhinitis (AR) with or without conjunctivitis (AR/C) is associated with a significant health and economic burden, and is often accompanied by asthma. Pharmacotherapies are the mainstay treatment options for AR and asthma, but guidelines also recommend allergy immunotherapy (AIT). Unlike pharmacotherapies, AIT has the ability to modify the underlying immunologic mechanisms of AR and asthma with the potential for long-term benefits after treatment is discontinued. Read More

    Therapeutic Effects of Korean Red Ginseng Extract in a Murine Model of Atopic Dermatitis: Anti-pruritic and Anti-inflammatory Mechanism.
    J Korean Med Sci 2017 Apr;32(4):679-687
    Department of Dermatology, The Catholic University of Korea College of Medicine, Incheon St. Mary's Hospital, Incheon, Korea.
    Korean red ginseng (KRG) and ginsenosides exhibit diverse biological effects, including anti-inflammatory and anti-allergic. We aimed to investigate the therapeutic effect of KRG in a murine model of atopic dermatitis (AD) is mediated whether by diminishing the pruritus or by suppressing the inflammation. Thirty NC/Nga mice were randomly divided to 5 groups. Read More

    1 OF 15